We would love to hear your thoughts about our site and services, please take our survey here.
So if Spreadex are increasing their stake does that mean they are hedging a net call position for their customers? I think so.
Aldo today there is an article from the uni of East Anglia, who I believe are partners with obd, in that well known tome of financial advice, Known as "the Sun"
I don't see how you can say we lost a good deal, if you are talking about aaqa, the deal was 2£ cash + £10 in aaqa shares which turned out to be worth nothing even before Candy attempted to freeze the assets. So the current share price is unrealistically low because of the outstanding legal case between Candy and Bonnier and one or both of them are most likely sellers so until that is sorted it will be difficult to make much progress, however the potential is clear and the financials are f solid.
That's a completely different company with a similar name.
Should be an announcement on consumer interest which closed at 4:30 today, if it is the same as the institution and insiders then it should be good.
Look very good except this what is this about -
"So as to better reflect the underlying performance of the business, the Company reports an exceptional one-off cost in relation to an individual contract which has been deemed to be onerous (US$8.9 million). This includes the H1 contract net loss (US$1.8 million) and the future estimated net loss (US$7.1 million) which has been provided for in full as at 30 June 2023"
So how is the wind down going to be achieved? Do we get lots of special dividends? So far it seems the nav had dropped and along with it the sp with nothing communicated.
So that's a yield of over 11% if you buy today.
According to this Sanofi and Pfizer already settled with James last year, I am not sure that settling like this makes it go away., however I see that they don't have any good options https://www.fiercepharma.com/pharma/gsks-first-state-level-zantac-trial-delayed-judge-reviews-science-both-sides-argument-report
Oxford Biodynamics granted US Foundation of NIH PACT Award for prognosis of cancer patients with IO-triggered Hyper-Progressive Disease
another $760,000 grant